Umezawa H
Nouv Presse Med. 1982 Nov 18;11(46):3379-84.
The advent of strains resistant to antibiotics in some patients has led to reorientation of research in this field. Demonstration of the mechanism involved in resistance to aminosides has resulted in the development of derivatives active against these resistant strains. Dibekacin, a new aminoside, is the first semisynthetic antibiotic of this class to be developed, and represents the first application of carbohydrate chemistry to the industry. It possesses potent activity and very weak ototoxicity.
一些患者中出现对抗生素耐药的菌株，这使得该领域的研究方向发生了转变。对氨基糖苷类耐药机制的阐明促使了对这些耐药菌株有活性的衍生物的开发。新氨基糖苷类药物地贝卡星是该类中首个被开发的半合成抗生素，代表了碳水化合物化学在制药行业的首次应用。它具有强效活性且耳毒性极弱。
